- Sweden
- /
- Life Sciences
- /
- OM:MAGLE
Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings
When close to half the companies in Sweden have price-to-earnings ratios (or "P/E's") below 17x, you may consider Magle Chemoswed Holding AB (publ) (STO:MAGLE) as a stock to avoid entirely with its 36.2x P/E ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly elevated P/E.
Magle Chemoswed Holding could be doing better as its earnings have been going backwards lately while most other companies have been seeing positive earnings growth. It might be that many expect the dour earnings performance to recover substantially, which has kept the P/E from collapsing. If not, then existing shareholders may be extremely nervous about the viability of the share price.
Check out our latest analysis for Magle Chemoswed Holding
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Magle Chemoswed Holding.How Is Magle Chemoswed Holding's Growth Trending?
In order to justify its P/E ratio, Magle Chemoswed Holding would need to produce outstanding growth well in excess of the market.
If we review the last year of earnings, dishearteningly the company's profits fell to the tune of 12%. This has erased any of its gains during the last three years, with practically no change in EPS being achieved in total. So it appears to us that the company has had a mixed result in terms of growing earnings over that time.
Shifting to the future, estimates from the one analyst covering the company suggest earnings should grow by 83% over the next year. With the market only predicted to deliver 17%, the company is positioned for a stronger earnings result.
With this information, we can see why Magle Chemoswed Holding is trading at such a high P/E compared to the market. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.
The Key Takeaway
Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.
We've established that Magle Chemoswed Holding maintains its high P/E on the strength of its forecast growth being higher than the wider market, as expected. Right now shareholders are comfortable with the P/E as they are quite confident future earnings aren't under threat. Unless these conditions change, they will continue to provide strong support to the share price.
Plus, you should also learn about this 1 warning sign we've spotted with Magle Chemoswed Holding.
If you're unsure about the strength of Magle Chemoswed Holding's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:MAGLE
Magle Chemoswed Holding
Operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden.
Solid track record and good value.